TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05032664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based aromatherapy programme
Description: 1 hour individualised face-to-face training to family caregivers, and 3 weeks aromatherapy intervention delivered by family caregivers (aromatherapy inhalation 2 times per day, each for 1 hour, using 2 drops of Lavandula angustifolia essential oil.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Wait-list control, no intervention for 3 weeks, then provide home-based aromatherapy
Study: NCT04753346

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Spirometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Spirometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Spirometry
Study: NCT06785064

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Buddy Training and Support (BTS)
Description: Participants assigned to buddy training and support will be asked to identify an eligible friend or family member who is over 18 years old that can be their buddy. Study staff will contact the buddy to be sure they are eligible, willing, and have all the details they need. The participant's buddy will be asked to attend up to 6 training sessions with the study staff, so they can learn the best ways to support the participant during the program. After the buddy completes training, they will be asked to check in with the participant 1-2 times each week about their progress.
Study: NCT04753346

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Fitness Level
Description: Cardiopulmonary Exercise Test
Study: NCT05265793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Combined With Apatinib
Description: After signing the informed consent, the selected patients received Camrelizumab combined with Apatinib. Treatment until disease progression and intolerable adverse reactions occur
Study: NCT05857007

Intervention type: DEVICE
Intervention: Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids
Description: Ten patients with hyperglycemia or/and diabetes in the neuro ICU requires subcutaneous insulin with concomitant high dose glucocorticoids will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU
Study: NCT05438706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: Chidamide, an HDAC inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: Chidamide, an HDAC inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer.
Study: NCT06095050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: Superselective arterial embolization of hyperemic vasculature in the symptomatic shoulder (utilizing the IDE approved device: Lipiodol) followed by structured physical therapy sessions.
Study: NCT05438706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin \[diammine(1,1-cyclobutanedicarboxylato)platinum(II)\] is one of the most promising second generation platinum compounds. Its greater chemical stability in comparison with cisplatin accounts for its lower reactivity with nucleophilic sites of DNA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients.
Study: NCT04494529

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 12 mg betamethasone + placebo
Description: After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24 mg betamethasone
Description: After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Active Comparator group will receive the standard 2nd intramuscular injection of 12 mg of betamethasone.
Study: NCT04753346

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Fitness Level
Description: Cardiopulmonary Exercise Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Fitness Level
Description: Cardiopulmonary Exercise Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Fitness Level
Description: Cardiopulmonary Exercise Test

Intervention type: OTHER
Intervention: Cognitive Assessment
Description: Montreal Cognitive Assessment

Intervention type: OTHER
Intervention: Cognitive Assessment
Description: Montreal Cognitive Assessment

Intervention type: OTHER
Intervention: Cognitive Assessment
Description: Montreal Cognitive Assessment
Study: NCT06095050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.
Study: NCT05997602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-159
Description: 5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle.
Study: NCT06790355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multi-cancer early detection
Description: Blood collection for multi-cancer early detection（MCED）, followed by clinical diagnosis based on the results of MCED and standard-of-care screening
Study: NCT06790446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric training group (ECC)
Description: The first, preparatory phase, lasts two weeks, aiming at making the participant familiar with the principles of eccentric training. Participants first experience the muscle recruitment patterns (during two sessions), then are prepared to induce protective response from the plantar flexors, conditioning these muscles for higher subsequent eccentric intensities.~The aim of the second, training phase per se, which lasts six weeks, is to induce muscular and neurological adaptations through a steady increase in work intensity to stimulate muscle plasticity until the end of the program - varying volume, load and speed.~Perceived exertion is quantified using Borg's scale (expected rating between 3 and 6) to ensure sufficient work intensity and prevent excessive fatigue. Musculoskeletal pain is assessed before and after each session through a Visual Analog Scale (0-10). Verbal encouragements and advising on correct exercise execution are provided by the therapist along each session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The participant visits a physiotherapist depending on the prescription, as in current practice
Study: NCT06791512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody
Description: Participants in the experimental group will receive the neoadjuvant therapy regimen of mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody. And the first five doses received the neoadjuvant therapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) combined with sintilimab (200 mg, intravenous) and Bevacizumab (5 mg/kg, intravenous), and the sixth dose received the same regimen of mFOLFOX6 and PD-1 monoclonal antibody but not plus bevacizumab, in order to allow sufficient withdrawal time of Bevacizumab for surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Participants in the control group will receive the neoadjuvant therapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) alone.
Study: NCT06791967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based walking program
Description: The home-based walking intervention involves five walking sessions per week over 12 weeks, with a target of 3,000 additional steps per session beyond daily activities. In the first week, participants in the experimental group will wear a smart wristband upon waking to record their average daily steps, which will guide their walking goals. By the 7th week, participants are expected to achieve at least 3,000 extra steps per session, completed in 30 continuous minutes. The wristband, synced via Bluetooth to its companion app, can store up to one month of walking data. Weekly phone follow-ups will record participants' daily step counts. No additional cloud uploads of personal data are required.
Study: NCT04753346

Intervention type: OTHER
Intervention: Cognitive Assessment
Description: Montreal Cognitive Assessment
Study: NCT06786767

Intervention type: DRUG
Intervention: BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg
Description: As this is a non-interventional study, it is accordance with routing clinical practice. The assignment of patients to Trimbow 172/5/9 mcg should be made independently from the study.
Study: NCT06790667

Intervention type: DEVICE
Group type: OTHER
Intervention: Low Level Laser Therapy
Description: Participants in this arm will receive Low-Level Laser Therapy (LLLT) using a Gallium Aluminum Arsenide (GaAlAs) semiconductor diode laser. The treatment involves a wavelength range of 650-808 nm with a power output of 775 mW. The therapy is administered by exposing tender points around the temporomandibular joint (TMJ) to the laser for 2 minutes per session. Each participant will receive treatment on alternate days (three sessions per week) over the course of three weeks. The goal is to assess the effectiveness of LLLT in reducing pain and improving mouth opening in patients with myofascial pain associated with Temporomandibular Disorders (TMD).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)
Description: Participants in this arm will undergo Transcutaneous Electrical Nerve Stimulation (TENS), utilizing a four-electrode unit. The device will be set to deliver electrical impulses at a frequency of 150 Hz with a pulse width of 200 µs. Electrodes will be placed over the cutaneous region between the TMJ and coronoid process to stimulate the trigeminal and facial nerves. Each treatment session will last 15 minutes and occur on alternate days, three times a week for three weeks. This therapy aims to provide pain relief and improve jaw function for patients suffering from myofascial pain associated with TMD.
Study: NCT05854797

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Walking
Description: Adhering to FITT method, normal walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 3.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brisk Walking
Description: Adhering to FITT method, brisk walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 4.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)
Study: NCT06442566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Patch
Description: Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; \>80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Patch
Description: Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; \>80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: double-blinded randomization to placebo or transdermal buprenorphine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: double-blinded randomization to REAL intermittent theta burst (iTBS) rTMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation (TMS)
Description: double-blinded randomization to SHAM intermittent theta burst (iTBS) rTMS
Study: NCT06071390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animated- assisted video
Description: For the experimental group, 15 minutes prior to the endoscopy, the researcher provided insight into the procedure by showing them a 3-minute animated video titled Endocan. This video, crafted by Köse in 2019 for his doctoral dissertation, offers a succinct overview of the endoscopy procedure.
Study: NCT05698108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization (IASTM)
Description: Tools designed for soft tissue mobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Moist Hot pack, Ultrasound, Deep Friction Massage, Stretching and Strengthening Exercises.
Study: NCT05211661

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory Muscle Testing
Description: Comprehensive assessment of respiratory muscle function. Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
Study: NCT05387213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Huddles
Description: Brief multidisciplinary meeting occurring twice a week for staff working at a LTC home led by a Nurse Practitioner. Huddles focused on discussing resident-care and staff-wellbeing.
Study: NCT05185284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 400 mg, lyophilizate for preparation of concentrate for solution for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: 200 mg coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: 100 mg, lyophilizate for preparation of concentrate for solution for infusion
Study: NCT06790589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Oral Tablet [Synthroid]
Description: Round, colour coded, scored tablet debossed with SYNTHROID on one side and potency on the other side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine Oral Tablet [Synthroid]
Description: Round, colour coded, scored tablet debossed with SYNTHROID on one side and potency on the other side.
Study: NCT05410782

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Power Prenatal for Sperm
Description: A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm)
Study: NCT06790394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetaben F18
Description: Florbetaben F18 is a radioactive diagnostic agent being developed for the indication of PET imaging of the heart to detect amyloid pathology. All patients will receive two administrations of Florbetaben F18 at a radioactive dose of 300 megabecquerel (MBq).
Study: NCT04679389

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered orally or enterally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: administered orally or enterally
Study: NCT04535505

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology
Description: This is an observational study and there are no interventions. The purpose of the study is to compare the accuracy （including sensitivity and specificity）of the new CPA platform based on CRISPR technology detection method and the gold standard in detecting pertussis patients.
Study: NCT01089166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT04592848

Intervention type: OTHER
Intervention: Questionnaires
Description: Four Questionnaires in French will be sent to participants :~* 1 questionnaire about sexual and urinary symptoms before and after the surgery ;~* 1 validated questionnaire Female Sexual Function Index to assess sexual function over the past 4 weeks ;~* 1 validated questionnaire Body Image Scale to assess body image during the past week ;~* 1 validated questionnaire Stoma Quality of Life, only for patients with incontinent urostomy.~If the questionnaires are not returned 15 days after sending, a follow-up phone call will be made by one of the investigators.~The data collection will include both the answers to the questionnaires and the patients' computerized medical data:~* Pathology responsible for the urological disorders and date of onset of the disorders~* Date and Type of surgery performed~* Patient's age at the time of surgery~* Post-operative complications within one month of surgery
Study: NCT05308160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Tab
Description: This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
Study: NCT06791031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inclisiran
Description: Patients randomized to the inclisiran early intensified therapy arm will receive initial treatment with inclisiran sodium 300 mg (equivalent to inclisiran 284 mg) on moderate-intensity statin therapy (i.e., atorvastatin: 20 mg; rosuvastatin: 10 mg) during hospitalization for the index ACS (administered within 24 hours after randomization), regardless of baseline LDL-C levels and whether on stable statin treatment or not. Subsequent doses will be administered by healthcare professionals at the month 3 and month 9 study visits and documented in the patient's medical history, without dose adjustment throughout the study. The study only provided inclisiran as PCSK9 inhibitors in the inclisiran early arm. The baseline types and regiments of lipid-lowering drugs other than PCSK9 inhibitors were maintained throughout the study period in both experimental and control group.
Study: NCT05308160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
Study: NCT04564703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
Study: NCT03176498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cell
Description: Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets & Atorvastatin Calcium
Description: Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Enteric-coated Tablets & Atorvastatin Calcium
Description: Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.